June 5, 2025
Roundtable Broadcast
Roundtable Participants
Jeff Allen, PhD
Present and CEO
Friends of Cancer Research
Ron Bartek
Co-founder and President
Friedreich’s Ataxia Research Alliance
Allyson Berent, DVM, DACVIM
Chief Scientific Officer
Foundation for Angelman Syndrome Therapeutics
Co-Director
Angelman Syndrome Biomarker and Outcome Measure
Catherine Bollard, MBChB, MD
Senior Vice President and Chief Research Officer
Director, Center for Cancer and Immunology Research
Professor of Pediatrics and Immunology
Children’s National and The George Washington University
Thomas Cahill, MD, PhD
Founder and Managing Partner
Newpath Partners
Andrew M. Cameron, MD, PhD
Director
Department of Surgery
The Johns Hopkins University School of Medicine
Paula Cannon, PhD
Distinguished Professor of Microbiology and Immunology
Keck School of Medicine
University of Southern California
Terence R. Flotte, MD
Professor, Provost, Dean of UMass Chan Medical School
President, American Society of Gene and Cell Therapy
Charles A. Gersbach, PhD
John W. Strohbehn Distinguished Professor
Department of Biomedical Engineering
Director, Center for Advanced Genomic Technologies
Duke University
Bambi Grilley, RPh, CCRC, CCRP, CIP, RAC
Director, Clinical Research and Early Product Development
Center for Cell and Gene Therapy
Professor, Pediatrics
Baylor College of Medicine
Chief Regulatory Officer
International Society for Cell & Gene Therapy
Timothy Hunt, JD
Chief Executive Officer
Alliance for Regenerative Medicine
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Director Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Smilow Center for Translational Research
Donald B. Kohn, MD
Distinguished Professor:
– Microbiology, Immunology and Molecular Genetics
– Pediatrics, Hematology/Oncology
– Molecular and Medical Pharmacology
University of California, Los Angeles
Brett Kopelan, MA
Executive Director
The Dystrophic Epidermolysis Bullosa Research Association of America
David Liu, PhD
Richard Merkin Professor and Director of the Merkin Institute for Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University
Jayme Locke, MD, MPH
Vice President, Medical Development Xenotransplantation
United Therapeutics
Crystal Mackall, MD
Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine
Founding Director, Stanford Center for Cancer Cell Therapy
Director of the Parker Institute for Cancer Immunotherapy
Stanford University
Rachel McMinn, PhD
Founder and CEO
Neurogene
Sean J. Morrison, PhD
Investigator, Howard Hughes Medical Institute
Director, Children’s Research Institute at UT Southwestern
University of Texas Southwestern Medical Center
Dallas, Texas
Chair of Public Policy Committee
International Society for Stem Cell Research
Terry Pirovolakis
CEO & Founder
Elpida Therapeutics
Vinayak Prasad, MD, MPH
Director
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Michelle Rengarajan, MD, PhD
Physician-Scientist and Attending Endocrinologist
Massachusetts General Hospital
Instructor in Medicine
Harvard Medical School
Shengdar Q. Tsai, PhD
Associate Member, Department of Hematology, St. Jude Children’s Research Hospital
Co-chair, Steering Committee of NIH Somatic Cell Genome Editing Consortium
Fyodor Urnov, PhD
Professor of Molecular Therapeutics at University of California, Berkeley
Scientific Director at Innovative Genomics Institute
Nicole Verdun, MD
Super Office Director
Office of Therapeutic Products
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration